HCPCS Code Descriptor:
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
Route of Administration:
Potential NDC Listing Errors:
Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.
AKYNZEO is an Oncology-Anti-Emetic drug manufactured by Helsinn Therapeutics and administered via the Intravenous route of administration. The J Code: J1454 is aligned to the drug AKYNZEO.
AKYNZEO is an antiemetic that may treat acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy. It is adminstered intravenously and is commonly used with dexamethasone. AKYNZEO (J1454) is composed of neupitant and palonosetron. Fosnetupitant works by selectively binding neurokinin-1 receptors, whose activation are largely associated with delayed emesis. Palonosetron acts as a 5-HT3 receptor antagonist and prevents activation of 5-HT3 recpetors by serotonin, which is largely associated with acute emesis. AKYNZEO is contraindicated for pregnant women, patients with severe hepatic and renal issues, and patients taking CYP3A4 substrates or inducers. Patient assistance for this medication is available through the Helsinn Cares program.
Access Pricing and More By Registering
HCPCS Added Date:
HCPCS Effective Date:
HCPCS Short Description:
Inj fosnetupitant, palonoset
Billing and Coding Guide: